{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    7,
    9
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "a",
        "name": "Amendment a",
        "scope": {
          "id": "cdc8170f-b6ec-43b5-b9f4-e5d5678feb72",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "cb99e4cb-49fd-458a-ae1e-78dd58cbcc03",
          "code": {
            "id": "67830a5d-1b06-4ec1-bbdb-0d0766dfd6df",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "bd364cf4-4ac1-4c1b-9378-96504fdbbca8",
            "type": {
              "id": "f4370b77-cc92-4919-9256-ad495749c11b",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The main reason for preparation of this amendment was to update the protocol for a Phase 3 study of Nasal Glucagon (LY900018) compared to intramuscular glucagon for treatment of insulin-induced hypoglycemia in Japanese patients with diabetes mellitus.",
        "effectiveDate": "2017-12-05",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2"
        ],
        "previousVersion": "Original Protocol (2017-10-26)",
        "newVersion": "Amendment (a)"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "Japan",
        "instanceType": "Country",
        "code": "JP"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 1,
      "countryCount": 1,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Regional",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1"
      ],
      "regions": [
        "Asia"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "a",
        "effectiveDate": "2017-12-05",
        "summary": "The main reason for preparation of this amendment was to update the protocol for a Phase 3 study of Nasal Glucagon (LY900018) compared to intramuscular glucagon for treatment of insulin-induced hypoglycemia in Japanese patients with diabetes mellitus.",
        "previousVersion": "Original Protocol (2017-10-26)",
        "newVersion": "Amendment (a)",
        "reasons": [
          "Scientific",
          "Administrative"
        ]
      }
    ],
    "geographicScope": {
      "type": "Regional",
      "countries": [
        {
          "name": "Japan",
          "code": "JP"
        }
      ],
      "regions": [
        "Asia"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}